Our R&D and manufacturing activities are largely based on chemical synthesis, meaning we use considerable amounts of organic solvents and energy, generating waste and air emissions. We manage these environmental impacts through our integrated Health, Safety and Environment (HSE) approach. We define our overall priorities annually in our HSE Strategy and transform them into measurable targets and actions.
ISO 14001 and ISO 45001 are international standards setting the requirements for Environment and Health & Safety Management Systems respectively. The standards can be applied to one system to enable businesses to identify and control all relevant impacts and hazards resulting from normal operations and abnormal situations and improve performance.
The system consists of written procedures and annual performance targets, communicated and integrated into daily operations via training. Compliance and improvements are evaluated by internal and external auditors and the business’ senior management reviews the overall system performance annually.
Because we develop our own manufacturing processes, our chemists are mindful to use the least harmful substances. We aim to minimise any adverse environmental impacts in line with the principles of Green Chemistry.
We deploy the best available technologies when designing processes, technical utilities and facilities, to continuously improve our manufacturing processes. Where possible we use solvents with lower environmental impact and have increased our capabilities to recycle organic solvents in chemical production. This has allowed us to eliminate the need for thousands of tons of virgin materials and continue to save resources for production, transportation and waste management.
We partner with universities to develop new working methods. For instance, by introducing continuous processing. Here the product is produced in a continuous flow in significantly smaller equipment than used in traditional batch processes where large reactors are filled, emptied and cleaned between each process step. This offers great benefits in raw material and energy usage.
By combining continuous production with recycling principles, we can create a circular economy, integrating different manufacturing processes and reusing materials across different processes. Our Sustainability Strategy contains a circular economy aspiration to move away from the traditional linear ‘take-make-dispose’ manufacturing model to a more regenerative model. This is in line with the SDG 12 Responsible Consumption and Production.
There is an interest within the pharmaceutical industry to increase what can be recycled and reused in packaging materials. This is being pursued at the association level in close dialogue with relevant health authorities.
We acknowledge stakeholder concerns about pharmaceutical residues in the environment. These mainly come from patients’ excretion of medicines taken, to treat or prevent a disease. We test the environmental effects of new medicinal products and design processes with the least possible environmental impact.
We pursue approaches that balance healthcare needs and environmental considerations in line with EFPIA’s Eco-Pharmaco-Stewardship Initiative to minimise pharmaceuticals in the environment and UN Sustainability Development Goal 12 on responsible consumption and production.
Our environmental focus extends beyond our manufacturing processes. We lease office printers and company cars, and pursue return opportunities for laptops, smart phones and other e-waste.
Saving energy and reducing CO2 emissions are strategic priorities for Lundbeck.
With our own manufacturing processes, we obtain several sustainable opportunities.
We pursue our business purpose guided by several pillars and our Code of Conduct.
UK-NOTPR-0533 | April 2022